Glenmark Gets USFDA Nod to Expand RYALTRIS® Use for Children Aged 6–12 Years 🇺🇸💊

Glenmark Pharmaceuticals has received **U.S. FDA approval** to expand the use of its **RYALTRIS® Nasal Spray** for treating **Seasonal Allergic Rhinitis (SAR)** in children aged **6 years to less than 12 years**. Previously, the therapy was approved only for patients aged 12 years and above. ### **Key Highlights** ✅ USFDA approval extends RYALTRIS® use to children aged **6 years and above**. ✅ Approval is based on a **Phase 3 clinical trial** involving **446 children**, where the treatment significantly improved nasal allergy symptoms and demonstrated a favorable safety profile. ✅ Glenmark began **direct commercialization** of RYALTRIS® in the United States from **April 1, 2026**, giving the company full control over branding, distribution, market access, and customer engagement. ✅ RYALTRIS® is already approved in **56 countries**, with launches in **11 additional markets during FY26**, strengthening Glenmark's global respiratory franchise. ### **Why It Matters** The expanded pediatric approval increases Glenmark's addressable patient base in the U.S. allergy treatment market and reinforces its innovation-driven respiratory portfolio. Combined with direct commercialization, the company gains greater control over revenue generation and long-term brand building in the world's largest pharmaceutical market. --- Disclaimer: This content is for educational and informational purposes only and should not be considered investment advice. Investors should conduct their own research before making investment decisions. $GLENMARK